Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYBB | P04839 | 2/20 | 0.54 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.53 |
| ▸ | PIM1 | P11309 | 12/20 | 0.51 |
| ▸ | PIM2 | Q9P1W9 | 9/20 | 0.51 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.50 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.50 |
| ▸ | FLT3 | P36888 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.47 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13500803 | 0.87 | CYBB (0.61) | CYBBSLC2A1PIM1PIM2CYP1A2 | |
| SCHEMBL13501319 | 0.87 | SLC2A1 (0.63) | CYBBSLC2A1PIM1PIM2FLT3 | |
| SCHEMBL13501321 | 0.86 | SLC2A1 (0.57) | CYBBSLC2A1PIM1PIM2 | |
| SCHEMBL3563380 | 0.83 | CYBB (0.59) | CYBBSLC2A1PIM1PIM2FLT3 | |
| SCHEMBL13500717 | 0.82 | CYBB (0.61) | CYBBSLC2A1PIM1PIM2FLT3 | |
| SCHEMBL13500712 | 0.80 | CYBB (0.57) | CYBBSLC2A1PIM1PIM2FLT3 | |
| SCHEMBL13500816 | 0.79 | SLC2A1 (0.71) | CYBBSLC2A1PIM1PIM2FLT3 | |
| SCHEMBL13500789 | 0.79 | CYBB (0.68) | CYBBSLC2A1PIM1PIM2FLT3 | |
| SCHEMBL13500714 | 0.79 | CYBB (0.51) | CYBBSLC2A1PIM1PIM2FLT3 | |
| SCHEMBL3565469 | 0.79 | HPGD (0.62) | GABRA2GABRB2TRPM8GPR119CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7662826-B2 | Pyrazolo [1,5-a] pyrimidine derivative and nad (p) h oxidase inhibitor containing the same | SHIONOGI & CO., LTD. (JP) | 2010-02-16 | — | — | US | disclosed |
| US-7662826-B2 | Pyrazolo [1,5-a] pyrimidine derivative and nad (p) h oxidase inhibitor containing the same | SHIONOGI & CO., LTD. (JP) | 2010-02-16 | — | — | US | disclosed |
| US-20060089362-A1 | Pyrazolo [1,5-a] pyrimidine derivative and nad (p) h oxidase inhibitor containing the same | SHIONOGI & CO., LTD (JP) | 2006-04-27 | — | — | US | disclosed |
| EP-1505068-A1 | PYRAZOLO (1,5-a) PYRIMIDINE DERIVATIVE AND NAD(P)H OXIDASE INHIBITOR CONTAINING THE SAME | SHIONOGI & CO., LTD. (JP) | 2005-02-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060089362-A1 | Pyrazolo [1,5-a] pyrimidine derivative and nad (p) h oxidase inhibitor containing the same | NADK, PNPO, NQO1 | CYBB 21/4885SLC2A1 2073/4885PIM1 2270/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.